top of page
Pioneering live biotherapeutics
in the respiratory tract.
ASTHMA
Our innovative solution
Lact AS: development of a recombinant live biotherapeutic
to treat severe asthma
In the LactAs project, our consortium aims to engineer the first recombinant LBP designed to treat asthma patients who do not respond to current treatments by integrating several modes of action in a single live biotherapeutic strain:
▪ Promotion of tissue regeneration.
▪ Inhibition of Th2 response
▪ Degradation of excess DNA
▪ Modulation of microbiome dysbiosis
Public-Private Collaboration Project CPP2021-008552 (2022): 1,148,219€
Proyecto CPP2021-008552 financiado por MCIN/AEI /10.13039/501100011033 y por la Unión Europea NextGenerationEU/ PRTR
bottom of page